EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Onvansertib-mediated PLK1 inhibition impairs spermatogenesis in the murine testis

Xiao-Xuan Qi, Xin Feng, Wen-Rui Zhu, Tian-Yi Song, Hui-Ling Li, Qiang Liu, Chao-Yang Xu, Yan Yuan, Qing Cheng, Lai-Hua Li

Asian Journal of Andrology · 2026-11 · 28 (6) · 814-822

DOI: 10.4103/aja202635 ↗
AbstractBibliografische Angaben

Abstract

Onvansertib (ONV) is a selective inhibitor of polo-like kinase 1 (PLK1) and has promise in treating cancer. However, its potential effects on male reproductive function remain insufficiently characterized. In this study, male mice received clinically relevant doses of ONV by intragastric gavage for five consecutive days. Evaluations conducted on day 1, day 6, and day 35 after treatment revealed a marked increase in germ cell apoptosis accompanied by a significant reduction in epididymal sperm counts, whereas somatic cell architecture was preserved. Mechanistically, PLK1 inhibition by ONV led to a pronounced decrease in eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) phosphorylation. This disruption is likely linked to impaired meiotic centrosome maturation and aberrant spindle organization in germ cells. Collectively, these findings demonstrate that ONV preferentially induces apoptosis in germ cells via PLK1 suppression, thereby compromising spermatogenic capacity.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →